The use of interferon in melanoma patients: A systematic review

Cytokine and Growth Factor Reviews

Volumn 26, Issue 2, 2015, Pages 203-212

  Di Trolio, Rossella ^a   Simeone, Ester ^a   Di Lorenzo, Giuseppe ^b   Buonerba, Carlo ^b   Ascierto, Paolo Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Combination therapy; Immunotherapy; Interferon; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; INTERFERON; INTERLEUKIN 2; PEGINTERFERON ALPHA2B; RECOMBINANT GAMMA INTERFERON; VINBLASTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER STAGING; CONTINUOUS INFUSION; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYALGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; PROGNOSIS;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERFERONS; MELANOMA; PROGNOSIS;

EID: 84926527702     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.11.008     Document Type: Article

References (90)

1. SEER cancer statistics review, 1975-2009 (vintage 2009 populations) 2012, National Cancer Institute, Bethesda, MD, April. Available at: http://seer.cancer.gov/csr/1975_2009_pops09 [accessed 05.08.14]. N. Howlader, A.M. Noone, M. Krapcho, J. Garshell, D. Miller, S.F. Altekruse (Eds.).
2. Leiter U., Eigentler T., Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014, 810:120-140.
3. Eigentler T.K., Caroli U.M., Radny P., Garbe C. Palliative therapy of disseminated malignant melanoma: a systemic review of 41 randomized trials. Lancet Oncol 2003, 12:748-759.
4. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014, 10.1056/NEJMoa1406037.
5. Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014, 10.1056/NEJMoa1408868.
6. White R.R., Stanley W.E., Johnson J.L., Tyler D.S., Seigler H.F. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002, 235:879-887.
7. Morton D.L., Thompson J.F., Cochran A.J., Mozzillo N., Nieweg O.E., Roses D.F. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014, 370:599-609.
8. Ascierto P.A., Gogas H.J., Grob J.J., Algarra S.M., Mohr P., Hansson J., et al. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol 2013, 85(February (2)):149-161.
9. Ascierto P.A., Kirkwood J.M. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008, 6:62.
10. Wang W., Edington H.D., Rao U.N., Jukic D.M., Land S.R., Ferrone S. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 2007, 13:1523-1531.
11. Di Trolio R., Simeone E., Di Lorenzo G., Grimaldi A.M., Romano A., Ayala F., et al. Update on PEG-interferon α-2b as adjuvant therapy in melanoma. Anticancer Res 2012, 32:3901-3909.
12. Wang W., Edington H.D., Jukic D.M., Rao U.N.M., Land S.R., Kirkwood J.M. Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma. Cancer Immunol Immunother 2008, 57:1315-1321.
13. Yurkovetsky Z.R., Kirkwood J.M., Edington H.D., Marrangoni A.M., Velikokhatnaya L., Winans M.T., et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007, 13:2422-2428.
14. + melanoma tumor-infiltrating lymphocytes. J Immunother 2012, 35:400-408.
15. Moschos S.J., Edington H.D., Land S.R., Rao U.N., Jukic D., Shipe-Spotloe J., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3171.
16. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718.
17. Critchley-Thorne R.J., Yan N., Nacu S., Weber J., Holmes S.P., Lee P.P. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med 2007, 4:e176.
18. Côté A.L., Usherwood E.J., Turk M.J. Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res 2008, 68:1614-1617.
19. Ascierto P.A., Napolitano M., Celentano E., Simeone E., Gentilcore G., Daponte A., et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010, 8:76.
20. Balch C.M., Soong S.J., Atkins M.B., Buzaid A.C., Cascinelli N., Coit D.G. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 2004, 54:131-149.
21. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7-17.
22. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18:2444-2458.
23. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380.
24. Pectasides D., Dafni U., Bafaloukos D., Skarlos D., Polyzos A., Tsoutsos D., et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009, 27:939-944.
25. Chiarion-Sileni V., Del Bianco P., Romanini A., Guida M., Paccagnella A., Dalla Palma M., et al. Intensified High-dose intravenous interferon alpha 2b for adjuvant treatment of stage III melanoma: a randomized phase III Italian Melanoma Intergroup (IMI) trial (ISRCTN75125874). J Clin Oncol 2011, 29(Suppl.). abstract 8506.
26. Mao L., Si L., Chi Z., Cui C., Sheng X., Li S., et al. A randomised phase II trial of 1 month versus 1year of adjuvant high-dose interferon alpha-2b in high-risk acral melanoma patients. Eur J Cancer 2011, 47:1498-1503.
27. Gogas H., Bafaloukos D., Ioannovich J., Skarlos D., Polyzos A., Fountzilas G., et al. Tolerability of adjuvant high-dose interferon alpha-2b:1 month versus 1 year - a Hellenic Cooperative Oncology Group study. Anticancer Res 2004, 24:1947-1952.
28. Agarwala S.S., Lee S.J., Flaherty L.E., Smylie M., Kefford R.F., Carson W.E., et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). J Clin Oncol 2011, 29. abstract 8505.
29. Payne M.J., Argyropoulou K., Lorigan P., McAleer J.J., Farrugia D., Davidson N., et al. Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol 2014, 32:185-190.
30. Mohr P., Hauschild A., Trefzer U., Enk A., Tilgen W., Loquai C., et al. Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: final analysis of a randomized phase III DeCOGtrial (NCT00226408). J Clin Oncol 2012, 30. abstract 8504.
31. Ascierto P.A., Gogas H.J., Grob J.J., Algarra S.M., Mohr P., Hansson J., et al. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol 2013, 85:149-161.
32. Lens M.B., Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002, 20:1818-1825.
33. Gogas H., Bafaloukos D., Ioannovich J., Skarlos D., Polyzos A., Fountzilas G., et al. Interferon as adjuvant therapy for melanoma:an individual patient data meta-analysis of randomised trial (2007 ASCO Meeting Abstract 8526). J Clin Oncol 2007, 25(18 S):8526.
34. Wheatley K., Ives N., Hancock B., Gore M., Eggermont A., Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003, 29:241-252.
35. Pirard D., Heenen M., Melot C., Vereecken P. Interferon alpha as adjuvant postsurgical treatment of melanoma:a meta-analysis. Dermatology 2004, 208:43-48.
36. Mocellin S., Lens M.B., Pasquali S., Pilati P., Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013, 6(June):CD008955.
37. Mocellin S., Pasquali S., Rossi C.R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
38. Garbe C., Radny P., Linse R., Dummer R., Gutzmer R., Ulrich J., et al. Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol 2008, 19:1195-1201.
39. Eggermont A.M., Suciu S., Testori A., Santinami M., Kruit W.H., Marsden J., et al. Long term adjuvant pegylated interferon alfa-2b versus observation in resected stage III melanoma: long term results at 7.6 years. J Clin Oncol 2011, 29(Suppl.). abstract 8506.
40. Grob J.J., Dreno B., de la Salmonière P., Delaunay M., Cupissol D., Guillot B., et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998, 351:1905-1910.
41. Pehamberger H., Soyer H.P., Steiner A., Kofler R., Binder M., Mischer P., et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998, 16:425-429.
42. Hancock B.W., Wheatley K., Harris S., Ives N., Harrison G., Horsman J.M., et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study - United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004, 22:53-61.
43. Cascinelli N., Belli F., MacKie R.M., Santinami M., Bufalino R., Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001, 358:866-869.
44. Kleeberg U.R., Suciu S., Brocker E.B., Ruiter D.J., Chartier C., Liénard D., et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis. Eur J Cancer 2004, 40:390-402.
45. Hauschild A., Weichenthal M., Rass K., Linse R., Berking C., Böttjer J., et al. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of ≥1.5mm tumor thickness: results of a randomized phase III DeCOG trial. J Clin Oncol 2010, 28:841-8466.
46. Hauschild A., Weichenthal M., Rass K., Linse R., Ulrich J., Stadler R., et al. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. J Clin Oncol 2009, 27:3496-3502.
47. Eggermont A.M., Suciu S., MacKie R., Ruka W., Testori A., Kruit W., et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa-2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005, 366:1189-1196.
48. Hansson J., Aamdal S., Bastholt L., Brandberg Y., Hernberg M., Nilsson B., et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011, 12:144-152.
49. Eggermont A.M., Suciu S., Santinami M., Testori A., Kruit W.H., Marsden J., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126.
50. Grob J.J., Jouary T., Dréno B., Asselineau J., Gutzmer R., Hauschild A., et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study. Eur J Cancer 2013, 49:166-174.
51. Van Akkooi A.C., de Wilt J.H., Verhoef C., Eggermont A.M. Isolated tumor cells and long-term prognosis of patients with melanoma. Ann Surg Oncol 2008, 15:1547-1548.
52. Tarhini A.A., Stuckert J., Lee S., Sander C., Kirkwood J.M. Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 2009, 27:38-44.
53. Boon T., Coulie P.G., Van den Eynde B.J., Human van der Bruggen P. T cell responses against melanoma. Annu Rev Immunol 2006, 24:175-208.
54. Speeckaert R., van Geel N., Luiten R.M., van Gele M., Speeckaert M., Lambert J., et al. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma. Anticancer Res 2011, 31:3697-3703.
55. Speeckaert R., van Geel N., Vermaelen K.V., Lambert J., Van Gele M., Speeckaert M.M., et al. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2011, 24:334-344.
56. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006, 211:214-224.
57. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005, 102:9571-9576.
58. Côté A.L., Usherwood E.J., Turk M.J. Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle. Cancer Res 2008, 68:1614-1617. 10.1158/0008-5472.CAN-07-6012.
59. Moschos S.J., Edington H.D., Land S.R., Rao U.N., Jukic D., Shipe-Spotloe J., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3171.
60. Gibbs P., Anderson C., Pearlman N., LaClaire S., Becker M., Gatlin K., et al. A phase II study of neoadjuvant biochemotherapy for stage III melanoma. Cancer 2002, 94:470-476.
61. Buzaid A.C., Colome M., Bedikian A., Eton O., Legha S.S., Papadopoulos N., et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998, 8:549-556.
62. Lewis K.D., Robinson W.A., McCarter M., Pearlman N., O'Day S.J., Anderson C., et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 2006, 24:3157-3163.
63. Ascierto P.A., Daponte A., Parasole R., Perrone F., Caracò C., Melucci M., et al. Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. Cancer 2000, 89:1490-1494.
64. Daponte A., Signoriello S., Maiorino L., Massidda B., Simeone E., Grimaldi A.M., et al. Southern Italy Cooperative Oncology Group (SICOG). Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma. J Transl Med 2013, 11:38.
65. Young A.M., Marsden J., Goodman A., Burton A., Dunn J.A. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001, 13:458-465.
66. Bajetta E., Del Vecchio M., Nova P., Fusi A., Daponte A., Sertoli M.R., et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006, 17:571-577.
67. Atkins M.B., Hsu J., Lee S., Cohen G.I., Flaherty L.E., Sosman J.A., et al. Eastern Cooperative Oncology Group: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008, 26:5748-5755.
68. Keilholz U., Punt C.J., Gore M., Kruit W., Patel P., Lienard D., et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005, 23:6747-6755.
69. Eton O., Legha S.S., Bedikian A.Y., Lee J.J., Buzaid A.C., Hodges C., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2045-2052.
70. Ives N.J., Stowe R.L., Lorigan P., Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007, 25:5426-5434.
71. Riker A.I., Rossi G.R., Masih P., Alsfeld L.C., Denham F., Tennant L., et al. Combination immunotherapy for high-risk resected and metastatic melanoma patients. Ochsner J 2014, 14:164-174.
72. Egberts F., Gutzmer R., Ugurel S., Becker J.C., Trefzer U., Degen A., et al. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol 2011, 22:1667-1674.
73. Grignol V.P., Olencki T., Relekar K., Taylor C., Kibler A., Kefauver C., et al. A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 2011, 34:509-515.
74. Guenterberg K.D., Grignol V.P., Relekar K.V., Varker K.A., Chen H.X., Kendra K.L., et al. A pilot study of bevacizumab and interferon-α2b in ocular melanoma. Am J Clin Oncol 2011, 34:87-91.
75. Tarhini A.A., Cherian J., Moschos S.J., Tawbi H.A., Shuai Y., Gooding W.E., et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012, 30:322-328.
76. Coit D.G., Thompson J.A., Andtbacka R., Anker C.J., Bichakjian C.K., Carson W.E., et al. Melanoma, version 4.2014. J Natl Compr Canc Netw 2014, 12:621-629.
77. Anaya D.A., Xing Y., Feng L., Huang X., Camacho L.H., Ross M.I., et al. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 2008, 112:2030-2037.
78. Eggermont A.M., Suciu S., Testori A., Kruit W.H., Marsden J., Punt C.J., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48:218-225.
79. Bouwhuis M.G., Suciu S., Kruit W., Salès F., Stoitchkov K., Patel P., et al. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer 2011, 47:361-368.
80. Meyer S., Wild P.J., Vogt T., Bataille F., Ehret C., Gantner S., et al. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Exp Dermatol 2010, 19:e251-e257.
81. Mowen K.A., Tang J., Zhu W., Schurter B.T., Shuai K., Herschman H.R., et al. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 2001, 104:731-741.
82. Lenci R.E., Bevier M., Brandt A., Bermejo J.L., Sucker A., Moll I., et al. Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS ONE 2012, 7:e50692.
83. Gogas H., Kirkwood J.M., Falk C.S., Dafni U., Sondak V.K., Tsoutsos D., et al. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 2010, 116:4326-4333.
84. Bouwhuis M.G., Suciu S., Testori A., Kruit W.H., Salès F., Patel P., et al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies EORTC 18991. J Clin Oncol 2010, 28:2460-2466.
85. Bouwhuis M.G., Collette S., Suciu S., de Groot E.R., Kruit W.H., Ten Hagen T.L., et al. Changes of ferritin and CRP levels in melanoma patients treated with adjuvant interferon-a (EORTC 18 952) and prognostic value on treatment outcome. Melanoma Res 2011, 21:344-351.
86. Hofmann M.A., Kiecker F., Küchler I., Kors C., Trefzer U. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma. J Cancer Res Clin Oncol 2011, 137:455-462.
87. Simons D.L., Lee G., Kirkwood J.M., Lee P.P. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 2011, 9:52.
88. Ma C., Armstrong A.W. Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat 2014, 25:401-408.
89. Chen L.L., Gouw L., Sabripour M., Hwu W.J., Benjamin R.S. Combining targeted therapy with immunotherapy (interferon-α): rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies. Oncoimmunology 2012, 1:773-776.
90. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013, 19:1225-1231.